Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - fluorouracil - cutaneous cream - 50mg/1gram

Belgija - engleski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pierre fabre benelux sa-nv - fluorouracil 40 mg - cream - 40 mg/g - fluorouracil 40 mg/g - fluorouracil

Australija - engleski - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/g - cream - excipient ingredients: polysorbate 60; methyl hydroxybenzoate; purified water; stearyl alcohol; white soft paraffin; propylene glycol; propyl hydroxybenzoate - solar and senile keratoses, bowen's disease.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/g - cream - excipient ingredients: polysorbate 60; methyl hydroxybenzoate; purified water; stearyl alcohol; white soft paraffin; propylene glycol; propyl hydroxybenzoate - solar and senile keratoses, bowen's disease.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

bausch health us, llc - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 5 mg in 1 g - carac is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp. fluorouracil may cause fetal harm when administered to a pregnant woman. fluorouracil is contraindicated in women who are or may become pregnant. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. no adequate and well-controlled studies have been conducted in pregnant women with either topical or parenteral forms of fluorouracil. one birth defect (ventricular septal defect) and cases of miscarriage have been reported when fluorouracil was applied to mucous membrane areas. multiple birth defects have been reported in the fetus of a patient treated with intravenous fluorouracil. animal reproduction studies have not been conducted with carac. fluorouracil, the active ingredient, has been shown to be teratogenic in mice, rats, and hamsters when administered parenterally at doses grea

Irska - engleski - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - fluorouracil sodium - solution for injection/infusion - 25 milligram(s)/millilitre - pyrimidine analogues; fluorouracil

Irska - engleski - HPRA (Health Products Regulatory Authority)

generics (uk) limited - fluorouracil - solution for inj/inf - 50 mg/ml - pyrimidine analogues - pyrimidine analogues - it is indicated in the treatment of the following malignancies and disease settings: in the treatment of metastatic colorectal cancer; as adjuvant treatment in colon and rectal cancer; in the treatment of advanced gastric cancer; in the treatment of advanced pancreatic cancer; in the treatment of advanced oesophageal cancer; in the treatment of advanced or metastatic breast cancer; as adjuvant treatment in patients with operable primary invasive breast cancer; in the treatment of inoperable locally advanced squamous cell carcinoma of the head and neck in previously untreated patients; in the treatment of locally recurrent or metastatic squamous cell carcinoma of the head and neck

Kanada - engleski - Health Canada

bausch health, canada inc. - fluorouracil - cream - 5% - fluorouracil 5% - misc. skin and mucous membrane agents

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - fluorouracil sodium - solution for injection - 25mg/1ml

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - fluorouracil sodium - solution for injection - 50mg/1ml